What is driving the intraday move in PRFN.SW stock today?

Intraday action stems from a sharp volume increase to **2,937,350** versus an average of **859,130**, pushing PRFN.SW stock down to **CHF 0.0362** as traders react to low liquidity and clinical/financing uncertainty.

What valuation and financial red flags should investors watch for PRFN.SW stock?

Watch negative EPS (**-0.001**), a negative PE metric, thin cash per share, and a price-to-book of **-15.24**. These metrics highlight small scale and binary clinical risk for PRFN.SW stock.

What is Meyka AI's view and forecast for PRFN.SW stock?

Meyka AI rates PRFN.SW as **62.87/100 (Grade B, HOLD)** and Meyka AI's forecast model projects **CHF 0.05** in 12 months, implying a **38.12%** upside versus the current **CHF 0.0362**; forecasts are not guarantees.

How should traders approach PRFN.SW stock given current liquidity?

Given the high relative volume and narrow market depth, intraday traders should use tight stops, limit order entries and small position sizes. Liquidity-driven moves can amplify PRFN.SW stock volatility.

CH Stocks

PRFN.SW Kinarus Therapeutics (SIX) down 8.12% to CHF 0.0362 intraday 19 Mar 2026: volume surge is key

ByDanny Kontos March 19, 2026March 19, 2026

The PRFN.SW stock of Kinarus Therapeutics Holding AG is trading lower intraday on 19 Mar 2026, down 8.12% to CHF 0.0362 after an early session spike in volume. Volume is currently 2,937,350 versus an average of 859,130, giving a relative volume of 3.42, which marks PRFN.SW among the most active names on SIX today. Short-term buyers and sellers are reacting to thin liquidity and price mean reversion signals, so intraday volatility is likely to remain elevated as traders price in clinical and funding updates.